On May 18, 2022 INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, reported that David Moss, Chief Financial Officer will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference (Press release, INmune Bio, MAY 18, 2022, View Source [SID1234614801]). The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!